Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BIIB

Biogen Inc

Jul 26 • 04:00PM ET

211.17

Dollar change -16.27
Percentage change -7.15	%

Healthcare • Drug Manufacturers - General • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: VTI VOO VO QQQ SPY IVV VTV XLV IBB VOE

Scroll to Statements

Index	NDX, S&P 500	P/E	26.38	EPS (ttm)	8.01	Insider Own	0.77%	Shs Outstand	144.90M	Perf Week	-6.73%
Market Cap	30.75B	Forward P/E	12.21	EPS next Y	17.30	Insider Trans	-0.09%	Shs Float	144.48M	Perf Month	-5.92%
Income	1.17B	PEG	6.68	EPS next Q	4.01	Inst Own	89.51%	Short Float	2.51%	Perf Quarter	4.30%
Sales	9.29B	P/S	3.31	EPS this Y	5.96%	Inst Trans	0.82%	Short Ratio	3.52	Perf Half Y	-14.23%
Book/sh	104.48	P/B	2.02	EPS next Y	10.90%	ROA	4.56%	Short Interest	3.63M	Perf Year	-20.39%
Cash/sh	7.38	P/C	28.62	EPS next 5Y	3.95%	ROE	8.04%	52W Range	189.44 - 278.95	Perf YTD	-18.39%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-18.05%	ROI	5.32%	52W High	-24.30%	Beta	-0.04
Dividend TTM	-	Quick Ratio	1.32	Sales past 5Y	-4.53%	Gross Margin	68.31%	52W Low	11.47%	ATR (14)	7.26
Dividend Ex-Date	-	Current Ratio	2.10	EPS Y/Y TTM	-62.75%	Oper. Margin	18.67%	RSI (14)	35.17	Volatility	2.92% 2.96%
Employees	7570	Debt/Eq	0.46	Sales Y/Y TTM	-2.49%	Profit Margin	12.56%	Recom	1.67	Target Price	280.90
Option/Short	Yes / Yes	LT Debt/Eq	0.44	EPS Q/Q	0.93%	Payout	0.00%	Rel Volume	2.14	Prev Close	227.44
Sales Surprise	-0.80%	EPS Surprise	5.78%	Sales Q/Q	-5.62%	Earnings	Aug 01 BMO	Avg Volume	1.03M	Price	211.17
SMA20	-7.36%	SMA50	-7.06%	SMA200	-8.71%	Trades		Volume	2,209,242	Change	-7.15%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-14-24	Reiterated	Needham	Buy	$305 → $300
Feb-14-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$315 → $240
Jan-24-24	Downgrade	UBS	Buy → Neutral	$311 → $276
Dec-20-23	Resumed	Cantor Fitzgerald	Overweight	$311
Dec-07-23	Upgrade	Raymond James	Mkt Perform → Outperform	$283
Sep-06-23	Initiated	HSBC Securities	Buy	$360
Jul-27-23	Initiated	Scotiabank	Sector Outperform	$327
Jul-24-23	Reiterated	UBS	Buy	$346 → $335
May-01-23	Upgrade	Guggenheim	Neutral → Buy	$270 → $350
Apr-17-23	Upgrade	Piper Sandler	Neutral → Overweight	$280 → $346
Oct-26-22	Upgrade	Goldman	Neutral → Buy	$220 → $370
Oct-13-22	Upgrade	Stifel	Hold → Buy	$223 → $299
Oct-07-22	Upgrade	Argus	Hold → Buy	$300
Sep-28-22	Upgrade	Robert W. Baird	Neutral → Outperform	$224 → $340
Sep-28-22	Upgrade	Mizuho	Neutral → Buy	$207 → $270
Sep-28-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$217 → $360
Apr-18-22	Upgrade	Wells Fargo	Equal Weight → Overweight	$235 → $265
Mar-08-22	Downgrade	Stifel	Buy → Hold	$304 → $223
Mar-03-22	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$227 → $248
Feb-04-22	Reiterated	Wolfe Research	Peer Perform	$244 → $217

Show Previous Ratings

Today 05:12PM	S&P 500 Gains and Losses Today: 3M Stock Skyrockets After Beat-and-Raise Report (Investopedia) -7.15%
04:15PM	Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug (Investor's Business Daily)
01:14PM	Top Stock Movers Now: 3M, Charter Communications, Dexcom, and More (Investopedia)
10:48AM	EU Rejection of Alzheimers Drug Is Another Disappointment for Biogen (Barrons.com)
10:21AM	Biogen/Eisai's Alzheimer's Drug Leqembi Gets 'No Go' From European Drug Regulator's Advisory Panel, Cites Serious Side Events (Benzinga)
09:48AM	Loading…
09:48AM	European committee says Alzheimer's treatment Leqembi shouldn't get marketing approval (Associated Press Finance)
08:00AM	Is Eli Lilly Stock A Sell On A Second Stumble In Obesity Treatment? (Investor's Business Daily)
07:20AM	Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union (GlobeNewswire)
Jul-25-24 10:02AM	Analysts Estimate Biogen Inc. (BIIB) to Report a Decline in Earnings: What to Look Out for (Zacks)
04:52AM	Sage and Biogens SAGE-324 shows no benefit in essential tremor trial (Clinical Trials Arena)
Jul-24-24 04:07PM	Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails (Investor's Business Daily)
10:34AM	Sage Therapeutics Stock Slides as Pipeline Thins (Barrons.com)
09:37AM	Is Biogen (BIIB) an Underappreciated Stock? (Insider Monkey)
08:10AM	Biogen, Sage tremor drug fails key trial (BioPharma Dive)
06:30AM	Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor (Business Wire)
03:52AM	Loading…
Jul-23-24 03:52AM	Nanotechnology in medicine: Who are the leading public companies? (Medical Device Network)
Jul-22-24 04:27PM	Ionis Pharmaceuticals Surges Into Buy Zone As It, Possibly, Proves Biogen Wrong (Investor's Business Daily)
08:14AM	Ionis plots next steps for Angelman drug Biogen passed on (BioPharma Dive)
01:12AM	Sage Therapeutics/Biogens episodic therapy zuranolone could change MDD treatment (Clinical Trials Arena)
Jul-17-24 09:50AM	Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term (Zacks)
Jul-16-24 04:02PM	Three Surprising Names That Could Be On Biogen's Buyout Shortlist (Investor's Business Daily)
12:45PM	Investors in Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights BIIB (GlobeNewswire)
11:55AM	Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense (Investor's Business Daily)
05:10AM	Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing (GlobeNewswire)
04:00AM	Biogen Inc Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - BIIB (PR Newswire)
Jul-12-24 08:00AM	Eli Lilly Overcomes Biden-Tied Stumble To Rise Again Is Lilly Stock Now A Buy? (Investor's Business Daily)
Jul-10-24 03:25PM	ADM Hires 3M CFO Amid Government Investigation (Investopedia)
01:08PM	Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights BIIB (GlobeNewswire)
Jul-09-24 07:51PM	Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB (PR Newswire)
Jul-05-24 06:20AM	3 Highly Rated Biotech Stocks for Your July Buy List (InvestorPlace)
12:37PM	Loading…
Jul-03-24 12:37PM	Top Stock Movers Now: Tesla, Paramount Global, Biogen, and More (Investopedia)
11:14AM	Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence (Pharmaceutical Technology)
11:14AM	FDA Approves Eli Lilly's Alzheimer's Drug Kisunla (Investopedia)
08:00AM	Biden Just Knocked Eli Lilly Stock Off Its Pedestal Is It A Buy Or A Sell? (Investor's Business Daily)
07:55AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Jul-02-24 04:13PM	Eli Lilly Wins Long-Awaited Approval For Biogen-Rivaling Alzheimer's Drug (Investor's Business Daily)
02:16PM	Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai (Investor's Business Daily)
12:45PM	Biogen (BIIB) Slipped on Lower-Than-Expected Revenue Growth (Insider Monkey)
09:16AM	Biogen Completes Acquisition of Human Immunology Biosciences (GlobeNewswire)
Jul-01-24 01:00AM	10 clinical trials to watch in the second half of 2024 (BioPharma Dive)
Jun-29-24 08:45PM	C4 Therapeutics, Inc. (CCCC): Is This the Best Biotech Penny Stock to Buy Now? (Insider Monkey)
Jun-28-24 06:13AM	Eisai and Biogen launch LEQEMBI for Alzheimers in China (Pharmaceutical Technology)
Jun-27-24 09:02PM	Eisai and Biogen launch Alzheimer's drug Leqembi in China (Reuters)
07:39PM	LEQEMBI (Lecanemab) for the Treatment of Alzheimer's Disease Launched in China (GlobeNewswire)
02:33PM	Eli Lilly Has Sprinted 55% Higher This Year Is It A Buy On The Weight-Loss Opportunity? (Investor's Business Daily)
Jun-26-24 05:45AM	Shareholders of Biogen Inc. Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB (PR Newswire)
03:12AM	Pharma M&A: The top high value deals in 2023 (Pharmaceutical Technology)
Jun-25-24 08:37AM	Is the Options Market Predicting a Spike in Biogen (BIIB) Stock? (Zacks)
Jun-24-24 09:50AM	Biogen Inc. (BIIB) is a Top-Ranked Momentum Stock: Should You Buy? (Zacks)
07:30AM	TOFIDENCE (tocilizumab), a Biosimilar Referencing ROACTEMRA , Approved in the European Union (GlobeNewswire)
Jun-20-24 01:38PM	Is Eli Lilly Stock A Buy After FDA Advisors Back Its Alzheimer's Drug? (Investor's Business Daily)
Jun-17-24 07:00AM	Two Is Better Than One in the Alzheimers Market (The Wall Street Journal)
01:12AM	ALS pipeline suffers a major hit as Biogens Tofersen fails phase iii trial (Clinical Trials Arena)
Jun-15-24 04:00PM	The 3 Best Healthcare Stocks to Buy in June 2024 (InvestorPlace)
Jun-14-24 06:45PM	Morningstar \| A Weekly Summary of Stock Ideas and Developments in the Companies We Cover (Morningstar Research)
05:45AM	Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB (PR Newswire)
Jun-11-24 04:07PM	Eli Lilly Seesaws On FDA Win, And Pushes Alzheimer's Stocks Prothena, Eisai Lower (Investor's Business Daily)
12:25PM	FDA Advisers Like Lillys Alzheimers Drug. Its Good News for Biogen. (Barrons.com)
12:20PM	Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win (Investor's Business Daily)
08:45AM	Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises (GlobeNewswire)
08:22AM	Donanemab approval would fuel growth of amyloid-blocking Alzheimers drugs, analysts say (BioPharma Dive)
07:35AM	5 Things to Know Before the Stock Market Opens (Investopedia)
Jun-10-24 10:12PM	Eli Lilly Stock Gains After FDA Advisors Recommend Alzheimer's Drug Donanemab (Investopedia)
05:17PM	FDA Panelists Unanimously Back Eli Lilly's Biogen-Rivaling Alzheimer's Drug (Investor's Business Daily)
04:18PM	FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment (Yahoo Finance)
10:27AM	Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug (Investor's Business Daily)
09:54AM	Biogen (BIIB) & Eisai's Leqembi sBLA Gets FDA Acceptance (Zacks)
Jun-09-24 07:37PM	FDA Accepts Eisai's Filing of LEQEMBI (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease (GlobeNewswire)
Jun-07-24 02:00PM	Eli Lilly Is Trading At A Record High Ahead Of A Key FDA Meeting Is It A Buy? (Investor's Business Daily)
11:41AM	Analyst Report: Biogen Inc. (Morningstar Research)
Jun-06-24 05:23PM	The 3 Most Undervalued Pharma Stocks to Buy in June 2024 (InvestorPlace)
09:50AM	Here's Why Biogen Inc. (BIIB) is a Strong Momentum Stock (Zacks)
05:45AM	Biogen Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before July 22, 2024 to Discuss Your Rights - BIIB (PR Newswire)
Jun-03-24 07:30AM	Biogen and Delta Flight Products to Collaborate with Advocates and Patients to Inform the Future of Accessible Air Travel (GlobeNewswire)
Jun-02-24 07:00AM	Top Stocks To Watch in June (Investopedia)
May-31-24 12:25PM	Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder (Benzinga)
11:42AM	Biogen Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information BIIB (GlobeNewswire)
10:17AM	Biogen (BIIB) Gets EU Approval for Rare Disease Drug Qalsody (Zacks)
08:00AM	How To Invest: Using Shorter-Term Moving Averages To Trade Stocks (Investor's Business Daily)
04:25AM	European Commission approves Biogens QALSODY for ALS treatment (Pharmaceutical Technology)
May-30-24 04:51PM	Biogen Receives European Commission Approval for QALSODY (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS (GlobeNewswire)
08:30AM	Is Eli Lilly Stock A Buy On A Recent Crohn's Disease-Related Rally? (Investor's Business Daily)
May-29-24 10:27AM	Interim results of IGNAZ trial sheds positive light on felzartamab for IgAN (Clinical Trials Arena)
07:02AM	Jeito Capital announces the acquisition by Merck & Co (NYSE: MRK) of its portfolio company EyeBio for a potential value of $3 billion (GlobeNewswire)
May-28-24 11:21AM	Amyotrophic Lateral Sclerosis Market On Track For USD 1,271.6 Mn Revenue By 2033, Growing At 6.5% CAGR Dimension Market Research (GlobeNewswire)
May-27-24 06:35AM	South Koreas MFDS approves Eisai-Biogens LEQEMBI for Alzheimers (Pharmaceutical Technology)
03:02AM	The Biggest Biotechnology Company in Europe (Insider Monkey)
May-25-24 11:15PM	The Biggest Publicly Traded Biotech Company (Insider Monkey)
11:10PM	20 Biggest Publicly Traded Biotech Companies (Insider Monkey)
May-24-24 11:31AM	Why Is Biogen (BIIB) Up 7.7% Since Last Earnings Report? (Zacks)
May-23-24 10:06AM	Biogen (BIIB) to Buy HI-Bio to Expand Rare Disease Pipeline (Zacks)
08:54AM	Biogen enters deal to acquire HI-Bio for $1.8bn (Pharmaceutical Technology)
May-22-24 07:28PM	Biogen Buys Biotech Firm HI-Bio to Boost Its Immunology Portfolio (Investopedia)
09:55AM	Biogen is buying up an immune drug developer for $1.8 billion (Quartz)
08:25AM	Biogen says hello to HI-Bio, inking $1.15B buyout to expand in immunology (FierceBiotech.com)
07:37AM	Biogen in up to $1.8 billion deal as rare diseases take center stage (Reuters)
07:30AM	Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences (GlobeNewswire)
07:19AM	Biogen, looking to diversify, acquires immune drugmaker HI-Bio for $1.15B (BioPharma Dive)
May-21-24 09:50AM	Why Biogen Inc. (BIIB) is a Top Momentum Stock for the Long-Term (Zacks)
May-17-24 06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace)

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Keeney Adam	Head of Corporate Development	May 01 '24	Option Exercise	0.00	938	0	938	May 03 08:00 PM
Singhal Priya	Head of Development	Apr 02 '24	Sale	213.09	93	19,817	4,886	Apr 03 08:24 PM
Murphy Nicole	Head of Pharm Ops and Tech	Apr 01 '24	Option Exercise	0.00	240	0	9,751	Apr 03 08:11 PM
Singhal Priya	Head of Development	Feb 22 '24	Sale	221.23	262	57,962	4,886	Feb 26 07:54 PM
Singhal Priya	Head of Development	Feb 16 '24	Option Exercise	0.00	1,208	0	5,429	Feb 21 09:27 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 16 '24	Option Exercise	0.00	5,037	0	52,506	Feb 21 09:39 PM
Gregory Ginger	EVP, Human Resources	Feb 16 '24	Option Exercise	0.00	4,704	0	14,341	Feb 21 09:36 PM
Izzar Rachid	Head of Global Product Strat.	Feb 16 '24	Option Exercise	0.00	2,017	0	10,014	Feb 21 09:33 PM
Kramer Robin	Chief Accounting Officer	Feb 16 '24	Option Exercise	0.00	1,345	0	6,354	Feb 21 09:31 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 16 '24	Option Exercise	0.00	6,720	0	20,692	Feb 21 09:29 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 16 '24	Option Exercise	0.00	1,260	0	9,624	Feb 21 09:28 PM
Singhal Priya	Head of Development	Feb 16 '24	Sale	221.49	108	23,921	5,148	Feb 21 09:27 PM
Rowinsky Eric K	Director	Feb 15 '24	Buy	222.54	455	101,256	20,629	Feb 20 09:13 PM
Singhal Priya	Head of Development	Feb 12 '24	Sale	239.45	419	100,330	4,516	Feb 13 06:06 PM
Izzar Rachid	Head of Global Product Strat.	Feb 09 '24	Option Exercise	0.00	1,515	0	9,081	Feb 13 06:00 PM
Singhal Priya	Head of Development	Feb 09 '24	Option Exercise	0.00	1,212	0	5,309	Feb 13 06:06 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 09 '24	Option Exercise	0.00	2,272	0	9,529	Feb 13 06:04 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 09 '24	Option Exercise	0.00	3,257	0	17,555	Feb 13 06:03 PM
Kramer Robin	Chief Accounting Officer	Feb 09 '24	Option Exercise	0.00	833	0	5,523	Feb 13 06:01 PM
Gregory Ginger	EVP, Human Resources	Feb 09 '24	Option Exercise	0.00	2,158	0	11,778	Feb 13 06:14 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 09 '24	Option Exercise	0.00	2,575	0	50,021	Feb 13 05:56 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Feb 08 '24	Option Exercise	0.00	2,335	0	15,063	Feb 09 08:03 PM
Murphy Nicole	Head of Pharm Ops and Tech	Feb 08 '24	Option Exercise	0.00	2,101	0	7,895	Feb 09 08:01 PM
Kramer Robin	Chief Accounting Officer	Feb 08 '24	Option Exercise	0.00	788	0	4,943	Feb 09 08:06 PM
Gregory Ginger	EVP, Human Resources	Feb 08 '24	Option Exercise	0.00	1,635	0	10,118	Feb 09 08:14 PM
Izzar Rachid	Head of Global Product Strat.	Feb 08 '24	Option Exercise	0.00	2,043	0	8,187	Feb 09 08:11 PM
ALEXANDER SUSAN H	EVP Chief Legal Officer	Feb 08 '24	Option Exercise	0.00	2,190	0	48,101	Feb 09 08:16 PM
Singhal Priya	Head of Development	Feb 02 '24	Sale	245.93	634	155,920	4,097	Feb 05 06:38 PM
Singhal Priya	Head of Development	Feb 01 '24	Option Exercise	0.00	1,828	0	5,292	Feb 05 06:38 PM
Singhal Priya	Head of Development	Dec 11 '23	Sale	248.00	110	27,280	3,464	Dec 12 05:06 PM
Kramer Robin	Chief Accounting Officer	Dec 08 '23	Option Exercise	0.00	351	0	4,325	Dec 12 05:02 PM
Singhal Priya	Head of Development	Dec 08 '23	Option Exercise	0.00	426	0	3,780	Dec 12 05:06 PM
BIOGEN INC.	10% Owner	Sep 26 '23	Sale	0.50	6,000,000	3,000,000	17,652,466	Sep 28 05:30 PM
Singhal Priya	Head of Development	Sep 05 '23	Sale	269.43	431	116,124	3,354	Sep 06 06:06 PM
MCDONNELL MICHAEL R	EVP, Chief Financial Officer	Sep 01 '23	Option Exercise	0.00	5,285	0	14,060	Sep 06 06:08 PM
Singhal Priya	Head of Development	Sep 01 '23	Option Exercise	0.00	1,668	0	4,592	Sep 06 06:06 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BIIB

Biogen Inc

Upgrade your FINVIZ experience